#ESTRO2022 Vu Alicia congrats ! Nice work with Ulrike Schick and Bourbonne Vincent about reRT in HNSCC.

Brilliant review by Hawkins group on SBRT for HCC linkinghub.elsevier.com/retrieve/pii/S…

New ESTRO ACROP guidelines on RT for uncomplicated bone mets are out! 🦴☢️ We compiled evidence-based recommendations on ✔️Management of painful bone mets ✔️Techniques, dose/fractionation schedules ✔️Re-irradiation and RT of oligometastatic lesions doi.org/10.1016/j.rado…

Local Treatment of the Primary Tumor for... Metastatic Cancer (PRIME-TX) RT>>surg for low metastatic burden esp prostate and NPC direct your Qs to Jeff Ryckman Nicholas Zaorsky, MD MS Toms V Thomas,MD Alex Louie MD, PhD Eric Lehrer, MD they will take care of you poke Melvin LK CHUA | FRCR, PhD, FASCO redjournal.org/article/S0360-…

Heartiest congratulations to Bourbonne Vincent who passed his PhD viva on deep learning approaches to predict toxicity after RT successfully yesterday !! 👨‍🎓Thanks Vincent Jaouen for his co-direction and to all external examiners Sébastien Thureau Philippe Giraud Jean-Emmanuel Bibault, MD, PhD for their insighful comments

Spine SBRT: 28Gy vs 24Gy in 2 daily Fx - Prospective DB: 482 pts, 947 segments - Long median FU of 23.5 mo 👉 Reduced local failure in 28Gy cohort: 2a LF 11.1% vs 17.6%, sig. in MVA 👉 No increased rates of toxicity 👏 Contrats to arjun sahgal and team redjournal.org/article/S0360-…

eanm22.eanm.org/information/aw… It is a great honor to receive the EJNMMI Most Cited Paper Award, @officialEANM. Thanks to my supervisors (Ulrike Schick et Mathieu Hatt) and colleagues, LaTIM-u1101 and @CHRU_Brest for their support.

PACIFIC post-hoc exploratory efficacy/safety analysis from a subgroup of pts with EGFRm NSCLC ▶️PFS and OS outcomes with durvalumab similar to placebo ▶️👉🏽IO consolidation not the treatment of choice ▶️Results of studies invest. TKIs after CTRT awaited pubmed.ncbi.nlm.nih.gov/36841540/

1er patient inclus et recevant des nanoparticules d'oxyde d'hafnium dans l'essai international NANORAY au @CHRU_Brest : Traitement prometteur pour booster la radiotherapie dans les cancers ORL. Merci au Dr Prevot et à toute l'équipe ! Nanobiotix

NEW: Primary results from the LUNAR randomised, open-label, pivotal phase 3 study of Tumor Treating Fields w/ standard systemic therapy vs standard systemic therapy alone in metastatic NSCLC following progression on or after platinum-based therapy. thelancet.com/journals/lanon…

Twice daily radiotherapy to 54Gy BID ⬆️⬆️ OS and PFS in small cell #lungcancer as compared to 45Gy BID. compared to CONVERT and RTOG, higher once daily RT did not ⬆️ OS. #lcsm - abstract ➡️ shorturl.at/huDJ2 - time to change?

Here are the K-M curves for NSCLC-specific survival in the Henschke et al. IELCAP/IELCART comparison study of Surgery v SBRT for stage I NSCLC. #radonc Journal pre-proof: linkinghub.elsevier.com/retrieve/pii/S…

Comprehensive 1.5 T #MRlinac cardiac atlas for #RadOncs delineating 💓 cardiac structures for MR guided radiation therapy (#MRgRT) planning and delivery ➡️ phiro.science/article/S2405-…

RCT SOC+SBRTvsSOC alone in 106 oligoprogressive(5 or <Mets): ➡️PFS > in the SBRT+SOC. ➡️In NSCLCpts, SBRT+SOC,>4 times increase in PFS compared with SOC only. ↘️no benefit in breast pts. #oligomets #oligocare #SBRT ⁦The Lancet⁩ thelancet.com/journals/lance…

Top 2% mondial de Stanford University : 13 chercheurs de l’UBO classés en 2023 🏆 dans 7 champs de recherche différents 🌍🧬📡 Encore une preuve de la pluridisciplinarité de l’UBO, et de ses liens étroits avec les établissements nationaux de recherche CNRS 🌍 Ifremer 🌊 Inserm Grand Ouest

Top 2% citations 2023 #Stanford #LaTIM 5 ranked researchers: B. Cochener: Ophthalmology M. Hatt: AI oncology G. Quellec: AI ophthalmology F. Rousseau: AI brain development D. Visvikis: Multimodal Imaging, Radiotherapy Inserm Grand Ouest UBO - Univ. Brest IMT Atlantique

Thanks to CHU de Liège, Pierre Lovinfosse, Roland Hustinx and Philippe Coucke for my fellowship

In the ALINA phase 3 trial of adjuvant treatment for patients with resected ALK-positive non–small-cell lung cancer, disease-free survival at 2 years was 93.6% with the ALK inhibitor alectinib and 63.7% with standard chemotherapy. Full trial results: nej.md/3VUzf3M

Updated Trends in the Utilization of Brachytherapy in Cervical Cancer in the United States: A Surveillance, Epidemiology, and End-Results Study - International Journal of Radiation Oncology, Biology, Physics redjournal.org/article/S0360-…